These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 37712984)

  • 1. Oral health conditions in patients under antiresorptive therapy are comparable to unexposed during supportive periodontal care.
    Ciardo A; Simon MM; Awounvo S; Kim TS
    Clin Oral Investig; 2023 Nov; 27(11):6523-6536. PubMed ID: 37712984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Study of Oral Health Parameters and the Properties and Composition of Saliva in Oncological Patients with and without Medication-Related Osteonecrosis of the Jaw Who Take Bisphosphonates.
    Sobczak-Jaskow H; Kochańska B; Drogoszewska B
    Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374277
    [No Abstract]   [Full Text] [Related]  

  • 3. [Position paper on medication-related osteonecrosis of the jaw (MRONJ)].
    Svejda B; Muschitz Ch; Gruber R; Brandtner Ch; Svejda Ch; Gasser RW; Santler G; Dimai HP
    Wien Med Wochenschr; 2016 Feb; 166(1-2):68-74. PubMed ID: 26847441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interventions for managing medication-related osteonecrosis of the jaw.
    Beth-Tasdogan NH; Mayer B; Hussein H; Zolk O; Peter JU
    Cochrane Database Syst Rev; 2022 Jul; 7(7):CD012432. PubMed ID: 35866376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab.
    Wick A; Bankosegger P; Otto S; Hohlweg-Majert B; Steiner T; Probst F; Ristow O; Pautke C
    Clin Oral Investig; 2022 Mar; 26(3):2839-2852. PubMed ID: 34812959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs.
    Ghidini G; Manfredi M; Giovannacci I; Mergoni G; Sarraj A; Mureddu M; Giunta G; Bonanini M; Meleti M; Vescovi P
    Minerva Stomatol; 2017 Aug; 66(4):135-140. PubMed ID: 28497661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases.
    Otto S; Pautke C; Van den Wyngaert T; Niepel D; Schiødt M
    Cancer Treat Rev; 2018 Sep; 69():177-187. PubMed ID: 30055439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Prevention of Medication-related Osteonecrosis of the Jaw.
    Poxleitner P; Engelhardt M; Schmelzeisen R; Voss P
    Dtsch Arztebl Int; 2017 Feb; 114(5):63-69. PubMed ID: 28241916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review.
    Kawahara M; Kuroshima S; Sawase T
    Int J Implant Dent; 2021 May; 7(1):47. PubMed ID: 33987769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perceptions and attitudes of patients towards medication-related osteonecrosis of the jaw (MRONJ): a qualitative study in England.
    Sturrock A; Preshaw PM; Hayes C; Wilkes S
    BMJ Open; 2019 Mar; 9(3):e024376. PubMed ID: 30833319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surgical therapy for medication-related osteonecrosis of the jaw in osteoporotic patients treated with antiresorptive agents.
    Hauer L; Jambura J; Hrusak D; Chalupova M; Posta P; Rusnak S; Vyskocil V
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2020 Mar; 164(1):100-107. PubMed ID: 30647474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dental pathologies in tumor patients with bone metastases or multiple myeloma scheduled for antiresorptive therapy.
    Laimer J; Hechenberger M; Müller D; Walch B; Kolk A; Schnabl D; Schomaker M; Bruckmoser E
    Future Oncol; 2021 Jul; 17(21):2705-2711. PubMed ID: 33880956
    [No Abstract]   [Full Text] [Related]  

  • 13. Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention.
    Owosho AA; Liang STY; Sax AZ; Wu K; Yom SK; Huryn JM; Estilo CL
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 May; 125(5):440-445. PubMed ID: 29580668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral health condition in cancer patients under bisphosphonate therapy.
    Jardim Caldas R; Spíndola Antunes H; de Oliveira Rodini Pegoraro C; Ribeiro Guedes F; da Silva Santos PS
    Support Care Cancer; 2021 Dec; 29(12):7687-7694. PubMed ID: 34145489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS.
    Anastasilakis AD; Pepe J; Napoli N; Palermo A; Magopoulos C; Khan AA; Zillikens MC; Body JJ
    J Clin Endocrinol Metab; 2022 Apr; 107(5):1441-1460. PubMed ID: 34922381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Denosumab-related osteonecrosis of the jaw following non-surgical periodontal therapy: A case report.
    Diniz-Freitas M; Fernández-Feijoo J; Diz Dios P; Pousa X; Limeres J
    J Clin Periodontol; 2018 May; 45(5):570-577. PubMed ID: 29479739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteonecrosis of the jaws in patients under osteoporosis treatment: a nine-year experience report.
    Penoni DC; Canellas JVS; Silami MANC; Sader F; Pimentel GS; Leão ATT
    Arch Endocrinol Metab; 2023 May; 67(4):e000612. PubMed ID: 37252700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention and treatment of oral adverse effects of antiresorptive medications for osteoporosis - A position paper of the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Stomatology and Oral Pathology (Sobep), and Brazilian Association for Bone Evaluation and Osteometabolism (Abrasso).
    Madeira M; Rocha AC; Moreira CA; Aguiar ÁMM; Maeda SS; Cardoso AS; de Moura Castro CH; D'Alva CB; Silva BCC; Ferraz-de-Souza B; Lazaretti-Castro M; Bandeira F; Torres SR
    Arch Endocrinol Metab; 2021 May; 64(6):664-672. PubMed ID: 34033275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic Periodontal Infection and Not Iatrogenic Interference Is the Trigger of Medication-Related Osteonecrosis of the Jaw: Insights from a Large Animal Study (PerioBRONJ Pig Model).
    Troeltzsch M; Zeiter S; Arens D; Nehrbass D; Probst FA; Liokatis P; Ehrenfeld M; Otto S
    Medicina (Kaunas); 2023 May; 59(5):. PubMed ID: 37241232
    [No Abstract]   [Full Text] [Related]  

  • 20. CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw.
    Baba A; Goto TK; Ojiri H; Takagiwa M; Hiraga C; Okamura M; Hasegawa S; Okuyama Y; Ogino N; Yamauchi H; Kobashi Y; Yamazoe S; Munetomo Y; Mogami T; Nomura T
    Dentomaxillofac Radiol; 2018 May; 47(4):20170323. PubMed ID: 29365278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.